Form 4: Ecolab Director MacLennan Reports Stock Option Grant

Ecolab Inc. Director David MacLennan reported the acquisition of stock options and a change in beneficial ownership of common stock.

Summary

• David MacLennan, a Director at Ecolab Inc., has reported a transaction involving stock options.
• On May 15, 2026, MacLennan was granted a non-employee director stock option with an exercise price of $247.70.
• This option grants the right to buy 732 shares of common stock.
• The option vests cumulatively, with 25% becoming exercisable after each of the first three three-month periods following the grant date, and the remainder exercisable by the end of the fourth three-month period or the company's next annual meeting.
• In the event of a Change in Control, the option becomes immediately exercisable in full.
• Following these transactions, MacLennan's beneficial ownership includes 25,230.01 shares of common stock held directly.
• Additionally, he has indirect beneficial ownership of 709 shares held by sibling trusts and 3,500 shares held by the Kathleen F. MacLennan Revocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions (stock option grant) without providing new financial performance data or strategic shifts.

Positives

• Director MacLennan received a stock option grant, indicating continued alignment with shareholder interests.
• The option grant is structured with vesting over time, encouraging long-term commitment.
• The option becomes fully exercisable upon a Change in Control, providing potential upside for the director in such a scenario.

Negatives

• No negative financial or operational information is present in this Form 4 filing.

Risks

• The value of the stock option is subject to market fluctuations and the future performance of Ecolab Inc.'s stock.
• The vesting schedule means the full benefit of the option is not immediately realized.
• A Change in Control event, while potentially beneficial for the option holder, may indicate underlying strategic shifts or challenges for the company.

Future Outlook

The filing details the terms and vesting schedule of a stock option grant, with the option exercisable in stages over approximately one year and expiring in 2036. The full exercisability upon a Change in Control is also noted.

Management Comments

• The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the earlier of the last day of the fourth three-month period following its date of grant or the company's next annual meeting date; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full.
• The date listed in the Date Exercisable column represents the first vesting date.

Industry Context

StockSavvy.ai notes that the issuance of stock options to non-employee directors is a standard practice in the chemicals and water treatment industry, aligning executive compensation with long-term shareholder value and company performance.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially incentivizing performance that benefits the stock price.
• Management: The option grant is part of the compensation structure for non-employee directors.
• Employees: Indirect impact through potential company performance driven by director incentives.

Next Steps

• The stock option will vest incrementally over the next year.
• The option will expire on May 15, 2036, unless exercised earlier.
• The option becomes fully exercisable upon a Change in Control of Ecolab Inc.

Key Dates

Keywords

Ecolab Inc., ECL, Form 4, Stock Option, Director, Beneficial Ownership, Grant, Vesting, SEC Filing, Insider Trading